{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:47:16Z","timestamp":1778888836471,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2013,7,23]],"date-time":"2013-07-23T00:00:00Z","timestamp":1374537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s11010-013-1761-0","type":"journal-article","created":{"date-parts":[[2013,7,22]],"date-time":"2013-07-22T15:26:58Z","timestamp":1374506818000},"page":"123-135","source":"Crossref","is-referenced-by-count":44,"title":["Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms"],"prefix":"10.1007","volume":"383","author":[{"given":"Nathalia","family":"Daflon-Yunes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavio Eduardo","family":"Pinto-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael Silveira","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna Fortunato","family":"Novis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tandressa","family":"Berguetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael Rodrigues Soares","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Polycarpo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian M.","family":"Rumjanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,23]]},"reference":[{"issue":"10","key":"1761_CR1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96(10):3343\u20133356","journal-title":"Blood"},{"issue":"7","key":"1761_CR2","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105(7):2640\u20132653. doi: 10.1182\/blood-2004-08-3097","journal-title":"Blood"},{"issue":"2","key":"1761_CR3","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1124\/jpet.103.055574","volume":"307","author":"A Hamada","year":"2003","unstructured":"Hamada A, Miyano H, Watanabe H, Saito H (2003) Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther 307(2):824\u2013828. doi: 10.1124\/jpet.103.055574","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"1761_CR4","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","volume":"101","author":"FX Mahon","year":"2003","unstructured":"Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman JM, Melo JV (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101(6):2368\u20132373. doi: 10.1182\/blood.V101.6.2368","journal-title":"Blood"},{"issue":"3","key":"1761_CR5","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1182\/blood-2003-03-0993","volume":"102","author":"N Widmer","year":"2003","unstructured":"Widmer N, Colombo S, Buclin T, Decosterd LA (2003) Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 102(3):1142. doi: 10.1182\/blood-2003-03-0993","journal-title":"Blood"},{"issue":"9","key":"1761_CR6","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","volume":"104","author":"H Burger","year":"2004","unstructured":"Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump. Blood 104(9):2940\u20132942. doi: 10.1182\/blood-2004-04-1398","journal-title":"Blood"},{"issue":"7","key":"1761_CR7","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4161\/cbt.4.7.1826","volume":"4","author":"H Burger","year":"2005","unstructured":"Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K (2005) Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 4(7):747\u2013752","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"1761_CR8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/1078-0432.CCR-10-2250","volume":"17","author":"K Eechoute","year":"2011","unstructured":"Eechoute K, Sparreboom A, Burger H, Franke RM, Schiavon G, Verweij J, Loos WJ, Wiemer EA, Mathijssen RH (2011) Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res 17(3):406\u2013415. doi: 10.1158\/1078-0432.CCR-10-2250","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1761_CR9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","volume":"455","author":"RL Juliano","year":"1976","unstructured":"Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455(1):152\u2013162","journal-title":"Biochim Biophys Acta"},{"issue":"5088","key":"1761_CR10","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1360704","volume":"258","author":"SP Cole","year":"1992","unstructured":"Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258(5088):1650\u20131654. doi: 10.1126\/science.1360704","journal-title":"Science"},{"issue":"26","key":"1761_CR11","doi-asserted-by":"crossref","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","volume":"95","author":"LA Doyle","year":"1998","unstructured":"Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95(26):15665\u201315670. doi: 10.1073\/pnas.95.26.15665","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1761_CR12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","volume":"2","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2(1):48\u201358. doi: 10.1038\/nrc706","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1761_CR13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0609.2011.01689.x","volume":"87","author":"S Vaidya","year":"2011","unstructured":"Vaidya S, Ghosh K, Vundinti BR (2011) Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review. Eur J Haematol 87(5):381\u2013393. doi: 10.1111\/j.1600-0609.2011.01689.x","journal-title":"Eur J Haematol"},{"issue":"3","key":"1761_CR14","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"FX Mahon","year":"2000","unstructured":"Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96(3):1070\u20131079","journal-title":"Blood"},{"issue":"1","key":"1761_CR15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1590\/S0001-37652001000100007","volume":"73","author":"VM Rumjanek","year":"2001","unstructured":"Rumjanek VM, Trindade GS, Wagner-Souza K, de-Oliveira MC, Marques-Santos LF, Maia RC, Capella MA (2001) Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1. An Acad Bras Cienc 73(1):57\u201369","journal-title":"An Acad Bras Cienc"},{"issue":"1\u20132","key":"1761_CR16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1\u20132):55\u201363","journal-title":"J Immunol Methods"},{"key":"1761_CR17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.pharmtox.48.080907.180426","volume":"48","author":"MD Hall","year":"2008","unstructured":"Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM (2008) The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48:495\u2013535. doi: 10.1146\/annurev.pharmtox","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1761_CR18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1741-7015-9-99","volume":"9","author":"AM Eiring","year":"2011","unstructured":"Eiring AM, Khorashad JS, Morley K, Deininger MW (2011) Advances in the treatment of chronic myeloid leukemia. BMC Med 9:99. doi: 10.1186\/1741-7015-9-99","journal-title":"BMC Med"},{"issue":"5","key":"1761_CR19","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.leukres.2008.09.024","volume":"33","author":"Y Assef","year":"2009","unstructured":"Assef Y, Rubio F, Colo G, del Monaco S, Costas MA, Kotsias BA (2009) Imatinib resistance in multidrug-resistant K562 human leukemic cells. Leuk Res 33(5):710\u2013716. doi: 10.1016\/j.leukres.2008.09.024","journal-title":"Leuk Res"},{"issue":"1","key":"1761_CR20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0304-3835(03)00338-0","volume":"199","author":"M Kotaki","year":"2003","unstructured":"Kotaki M, Motoji T, Takanashi M, Wang YH, Mizoguchi H (2003) Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562\/ADM cell line. Cancer Lett 199(1):61\u201368","journal-title":"Cancer Lett"},{"issue":"7","key":"1761_CR21","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.exphem.2005.03.014","volume":"33","author":"H Rumpold","year":"2005","unstructured":"Rumpold H, Wolf AM, Gruenewald K, Gastl G, Gunsilius E, Wolf D (2005) RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp Hematol 33(7):767\u2013775. doi: 10.1016\/j.exphem.2005.03.014","journal-title":"Exp Hematol"},{"issue":"10","key":"1761_CR22","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.tips.2009.07.003","volume":"30","author":"MD Hall","year":"2009","unstructured":"Hall MD, Handley MD, Gottesman MM (2009) Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci 30(10):546\u2013556. doi: 10.1016\/j.tips.2009.07.003","journal-title":"Trends Pharmacol Sci"},{"issue":"14","key":"1761_CR23","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1158\/0008-5472.CAN-04-0143","volume":"64","author":"D Trompier","year":"2004","unstructured":"Trompier D, Chang XB, Barattin R, du Moulinet D\u2019Hardemare A, Di Pietro A, Baubichon-Cortay H (2004) Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1. Cancer Res 64(14):4950\u20134956. doi: 10.1158\/0008-5472.CAN-04-0143","journal-title":"Cancer Res"},{"issue":"5","key":"1761_CR24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0309-1651(86)90011-1","volume":"10","author":"JR Warr","year":"1986","unstructured":"Warr JR, Brewer F, Anderson M, Fergusson J (1986) Verapamil hypersensitivity of vincristine resistant Chinese hamster ovary cell lines. Cell Biol Int Rep 10(5):389\u2013399","journal-title":"Cell Biol Int Rep"},{"issue":"1","key":"1761_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.b.20013","volume":"61","author":"GB Cavalcanti Jr","year":"2004","unstructured":"Cavalcanti GB Jr, Vasconcelos FC, Pinto de Faria G, Scheiner MA, de Almeida Dobbin J, Klumb CE, Maia RC (2004) Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia. Cytometry B Clin Cytom 61(1):1\u20138. doi: 10.1002\/cyto.b.20013","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"1761_CR26","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1046\/j.1440-1711.1999.00837.x","volume":"77","author":"P Waring","year":"1999","unstructured":"Waring P, Mullbacher A (1999) Cell death induced by the Fas\/Fas ligand pathway and its role in pathology. Immunol Cell Biol 77(4):312\u2013317. doi: 10.1046\/j.1440-1711.1999.00837.x","journal-title":"Immunol Cell Biol"},{"issue":"7","key":"1761_CR27","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1182\/blood.V94.7.2414.417k01_2414_2423","volume":"94","author":"ME Smeets","year":"1999","unstructured":"Smeets ME, Raymakers RA, Vierwinden G, Pennings AH, Wessels H, de Witte T (1999) Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by downregulating multidrug resistance. Blood 94(7):2414\u20132423","journal-title":"Blood"},{"issue":"3","key":"1761_CR28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3109\/08923979909007126","volume":"21","author":"R Marzio","year":"1999","unstructured":"Marzio R, Mauel J, Betz-Corradin S (1999) CD69 and regulation of the immune function. Immunopharmacol Immunotoxicol 21(3):565\u2013582. doi: 10.3109\/08923979909007126","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"3","key":"1761_CR29","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.molonc.2008.07.003","volume":"2","author":"O Hantschel","year":"2008","unstructured":"Hantschel O, Gstoettenbauer A, Colinge J, Kaupe I, Bilban M, Burkard TR, Valent P, Superti-Furga G (2008) The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia. Mol Oncol 2(3):272\u2013281. doi: 10.1016\/j.molonc.2008.07.003","journal-title":"Mol Oncol"},{"issue":"4","key":"1761_CR30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.leukres.2006.07.016","volume":"31","author":"FC Vasconcelos","year":"2007","unstructured":"Vasconcelos FC, Cavalcanti GB Jr, Silva KL, de Meis E, Kwee JK, Rumjanek VM, Maia RC (2007) Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice. Leuk Res 31(4):445\u2013454. doi: 10.1016\/j.leukres.2006.07.016","journal-title":"Leuk Res"},{"issue":"6","key":"1761_CR31","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10637-007-9064-5","volume":"25","author":"FC Vasconcelos","year":"2007","unstructured":"Vasconcelos FC, Gattass CR, Rumjanek VM, Maia RC (2007) Pomolic acid-induced apoptosis in cells from patients with chronic myeloid leukemia exhibiting different drug resistance profile. Invest New Drugs 25(6):525\u2013533. doi: 10.1007\/s10637-007-9064-5","journal-title":"Invest New Drugs"},{"issue":"2","key":"1761_CR32","first-page":"471","volume":"26","author":"FR Reis","year":"2011","unstructured":"Reis FR, Vasconcelos FC, Pereira DL, Moellman-Coelho A, Silva KL, Maia RC (2011) Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia. Oncol Rep 26(2):471\u2013478. doi: 10.3892\/or.2011.1296","journal-title":"Oncol Rep"},{"issue":"3","key":"1761_CR33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cyto.b.20580","volume":"80","author":"FC Vasconcelos","year":"2011","unstructured":"Vasconcelos FC, Silva KL, Souza PS, Silva LF, Moellmann-Coelho A, Klumb CE, Maia RC (2011) Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients. Cytometry B Clin Cytom 80(3):158\u2013166. doi: 10.1002\/cyto.b.20580","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"1761_CR34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00001813-200103000-00010","volume":"12","author":"F Grandjean","year":"2001","unstructured":"Grandjean F, Bremaud L, Verdier M, Robert J, Ratinaud MH (2001) Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines. Anticancer Drugs 12(3):247\u2013258","journal-title":"Anticancer Drugs"},{"issue":"3","key":"1761_CR35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/(SICI)1097-0215(19960126)65:3<365::AID-IJC15>3.0.CO;2-9","volume":"65","author":"DC Zhou","year":"1996","unstructured":"Zhou DC, Ramond S, Viguie F, Faussat AM, Zittoun R, Marie JP (1996) Sequential emergence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines. Int J Cancer 65(3):365\u2013371. doi: 10.1002\/(SICI)1097-0215(19960126)65:3<365:AID-IJC15>3.0.CO;2-9","journal-title":"Int J Cancer"},{"issue":"1","key":"1761_CR36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1476-4598-5-55","volume":"5","author":"A Ertel","year":"2006","unstructured":"Ertel A, Verghese A, Byers SW, Ochs M, Tozeren A (2006) Pathway-specific differences between tumor cell lines and normal and tumor tissue cells. Mol Cancer 5(1):55. doi: 10.1186\/1476-4598-5-55","journal-title":"Mol Cancer"},{"issue":"42","key":"1761_CR37","doi-asserted-by":"crossref","first-page":"12163","DOI":"10.1021\/bi034149+","volume":"42","author":"J Karwatsky","year":"2003","unstructured":"Karwatsky J, Lincoln MC, Georges E (2003) A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity. Biochemistry 42(42):12163\u201312173. doi: 10.1021\/bi034149+","journal-title":"Biochemistry"},{"issue":"17","key":"1761_CR38","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1016\/j.bmc.2010.07.031","volume":"18","author":"R Barattin","year":"2010","unstructured":"Barattin R, Perrotton T, Trompier D, Lorendeau D, Di Pietro A, d\u2019Hardemare Adu M, Baubichon-Cortay H (2010) Iodination of verapamil for a stronger induction of death, through GSH efflux, of cancer cells overexpressing MRP1. Bioorg Med Chem 18(17):6265\u20136274. doi: 10.1016\/j.bmc.2010.07.031","journal-title":"Bioorg Med Chem"},{"issue":"8","key":"1761_CR39","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/cmdc.201100102","volume":"6","author":"E Genoux-Bastide","year":"2011","unstructured":"Genoux-Bastide E, Lorendeau D, Nicolle E, Yahiaoui S, Magnard S, Di Pietro A, Baubichon-Cortay H, Boumendjel A (2011) Identification of xanthones as selective killers of cancer cells overexpressing the ABC transporter MRP1. ChemMedChem 6(8):1478\u20131484. doi: 10.1002\/cmdc.201100102","journal-title":"ChemMedChem"},{"issue":"1\u20132","key":"1761_CR40","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.drup.2012.03.002","volume":"15","author":"KM Pluchino","year":"2012","unstructured":"Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM (2012) Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat 15(1\u20132):98\u2013105. doi: 10.1016\/j.drup.2012.03.002","journal-title":"Drug Resist Updat"},{"issue":"Pt 1","key":"1761_CR41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1042\/bj20011880","volume":"365","author":"A Pohl","year":"2002","unstructured":"Pohl A, Lage H, Muller P, Pomorski T, Herrmann A (2002) Transport of phosphatidylserine via MDR1 (multidrug resistance 1) P-glycoprotein in a human gastric carcinoma cell line. Biochem J 365(Pt 1):259\u2013268. doi: 10.1042\/BJ20011880","journal-title":"Biochem J"},{"issue":"6","key":"1761_CR42","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/(SICI)1097-0215(19980316)75:6<855::AID-IJC7>3.0.CO;2-U","volume":"75","author":"M Wartenberg","year":"1998","unstructured":"Wartenberg M, Frey C, Diedershagen H, Ritgen J, Hescheler J, Sauer H (1998) Development of an intrinsic P-glycoprotein-mediated doxorubicin resistance in quiescent cell layers of large, multicellular prostate tumor spheroids. Int J Cancer 75(6):855\u2013863. doi: 10.1002\/(SICI)1097-0215(19980316)75:6<855:AID-IJC7>3.0.CO;2-U","journal-title":"Int J Cancer"},{"issue":"1","key":"1761_CR43","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/0014-4827(91)90176-U","volume":"192","author":"A Myc","year":"1991","unstructured":"Myc A, DeAngelis P, Kimmel M, Melamed MR, Darzynkiewicz Z (1991) Retention of the mitochondrial probe rhodamine 123 in normal lymphocytes and leukemic cells in relation to the cell cycle. Exp Cell Res 192(1):198\u2013202","journal-title":"Exp Cell Res"},{"issue":"11","key":"1761_CR44","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/sj.cdd.4401081","volume":"9","author":"AA Ruefli","year":"2002","unstructured":"Ruefli AA, Tainton KM, Darcy PK, Smyth MJ, Johnstone RW (2002) P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ 9(11):1266\u20131272. doi: 10.1038\/sj.cdd.4401081","journal-title":"Cell Death Differ"},{"issue":"12","key":"1761_CR45","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1073\/pnas.95.12.7024","volume":"95","author":"MJ Smyth","year":"1998","unstructured":"Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW (1998) The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 95(12):7024\u20137029","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1761_CR46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0145-2126(00)00085-0","volume":"25","author":"KV Cullen","year":"2001","unstructured":"Cullen KV, Davey RA, Davey MW (2001) Drug resistance does not correlate with resistance to Fas-mediated apoptosis. Leuk Res 25(1):69\u201375","journal-title":"Leuk Res"},{"issue":"8","key":"1761_CR47","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/sj.cdd.4400303","volume":"4","author":"F Belloc","year":"1997","unstructured":"Belloc F, Cotteret S, Labroille G, Schmit V, Jaloustre C, Dumain P, Durrieu F, Reiffers J, Boisseau MR, Bernard P, Lacombe F (1997) Bcr-abl translocation can occur during the induction of multidrug resistance and confers apoptosis resistance on myeloid leukemic cell lines. Cell Death Differ 4(8):806\u2013814. doi: 10.1038\/sj.cdd.4400303","journal-title":"Cell Death Differ"},{"issue":"4","key":"1761_CR48","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/(SICI)1097-0215(19961115)68:4<535::AID-IJC21>3.0.CO;2-2","volume":"68","author":"Z Cai","year":"1996","unstructured":"Cai Z, Stancou R, Korner M, Chouaib S (1996) Impairment of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumor cells. Int J Cancer 68(4):535\u2013546. doi: 10.1002\/(SICI)1097-0215(19961115)68:4<535:AID-IJC21>3.0.CO;2-2","journal-title":"Int J Cancer"},{"issue":"1","key":"1761_CR49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0304-3835(01)00834-5","volume":"180","author":"M Notarbartolo","year":"2002","unstructured":"Notarbartolo M, Cervello M, Dusonchet L, Cusimano A, D\u2019Alessandro N (2002) Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins). Cancer Lett 180(1):91\u2013101","journal-title":"Cancer Lett"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-013-1761-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11010-013-1761-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-013-1761-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T11:26:35Z","timestamp":1596194795000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11010-013-1761-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,23]]},"references-count":49,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["1761"],"URL":"https:\/\/doi.org\/10.1007\/s11010-013-1761-0","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,23]]}}}